Orgenesis Announces Expanded Partnership Between Octomera and UC Davis Through CIRM Grant Funding
November 02, 2023 08:00 ET
|
Orgenesis Inc.
GERMANTOWN, Md., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
Orgenesis Announces Withdrawal of Proposed Public Offering
October 30, 2023 21:30 ET
|
Orgenesis Inc.
GERMANTOWN, Md., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
Orgenesis Announces Proposed Underwritten Public Offering
October 30, 2023 16:07 ET
|
Orgenesis Inc.
GERMANTOWN, Md., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
CGT Global and Octomera Enter Agreement to Expand Cell & Gene Therapy Development and Patient Access Across the United States
September 21, 2023 08:00 ET
|
Orgenesis Inc.
GERMANTOWN, Maryland, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
Cell and Gene Therapy Industry Pioneer & GMP Expert, Gerhard Bauer, Joins Orgenesis Business, Octomera, to Drive Continued Expansion of POCare Facilities and Service Support
September 06, 2023 07:00 ET
|
Orgenesis Inc.
GERMANTOWN, Md., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Orgenesis, a global biotech company working to unlock the full potential of cell and gene therapies (CGTs), continues to grow the infrastructure...
Orgenesis Provides Business Update for Second Quarter of 2023
August 11, 2023 07:00 ET
|
Orgenesis Inc.
Reports Progress in Advancing the Rollout of the POCare Platform and POCare Therapeutic Pipeline Orgenesis to Host Conference Call Today at 8:00 AM ET GERMANTOWN, Md., Aug. 11,...
Orgenesis Schedules Second Quarter 2023 Business Update Conference Call
August 10, 2023 08:30 ET
|
Orgenesis Inc.
GERMANTOWN, Md., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
Orgenesis Appoints Finance Veteran Elliot Maltz as its Chief Financial Officer
July 13, 2023 08:30 ET
|
Orgenesis Inc.
GERMANTOWN, Md., July 13, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
Orgenesis Announces Name Change of Morgenesis Business Unit to Octomera
July 11, 2023 07:00 ET
|
Orgenesis Inc.
GERMANTOWN, Md., July 11, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
Orgenesis and University of California, Davis Sign Partnership Agreement for Rollout of Cell and Gene Therapy Mobile Processing Units and Labs Throughout California
June 07, 2023 07:00 ET
|
Orgenesis Inc.
GERMANTOWN, Md. and DAVIS, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of...